[89zr]df-iab2m
Metastatic Prostate Cancer
ImaginAb, Inc.radiopharmaceuticalPhase 1/2Dormant
CC
46/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 37/ 100
- Competitive Position
- 73/ 100
Competitive context
252 Active assets in the Metastatic Prostate Cancer cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
PREDNISONE TABLETS Mayo Clinic | Phase 4 | BBB |
Fluciclovine VA Greater Los Angeles Healthcare System | Phase 4 | BBB |
LEUPROLIDE Mayo Clinic | Phase 4 | BBB |
Abiraterone Acetate Mayo Clinic | Phase 4 | BB |
PREDNISONE TABLETS Mayo Clinic | Phase 4 | BB |
View all 50 →
Same molecule, other indications
[89zr]df-iab2m is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →